BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
18670 - Sun Protection Factor Assay
Not Applicable
Completed
- Conditions
- Sunscreening Agent
- Interventions
- Drug: Coppertone (BAY987518)
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2018-12-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 10
- Registration Number
- NCT02801929
Sun Protection Factor Assay
Not Applicable
Completed
- Conditions
- Sunscreening Agent
- Interventions
- Drug: Coppertone (BAY987517)
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2018-12-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 10
- Registration Number
- NCT02803008
To Assess the Safety of a Sunscreen Product
Not Applicable
Completed
- Conditions
- Sunscreening Agents
- Interventions
- Drug: SPF 50 Y65 110 (BAY 987516)
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2018-12-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 107
- Registration Number
- NCT02803320
Test the Phototoxicity of Sunscreen Products
Not Applicable
Completed
- Conditions
- Sunscreen Agents
- Interventions
- Drug: SPF 50 Y65 110 (BAY987519)Drug: SPF 50 Y51 002 (BAY987519)Drug: SPF 15 V27 104 (BAY987519)
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2018-12-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 32
- Registration Number
- NCT02802930
Sun Protection Factor Assay
Not Applicable
Completed
- Conditions
- Sunscreening Agent
- Interventions
- Drug: Coppertone (BAY987516)
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2018-12-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 15
- Registration Number
- NCT02803060
To Evaluate Eye Installation-Tear Free
Not Applicable
Completed
- Conditions
- Sunscreening Agents
- Interventions
- Drug: SPF 50 X15 158 (BAY 987516)Drug: SPF 50 X57 162 (BAY 987516)Drug: SPF 50 Y49 091 (BAY 987516)Drug: SPF 50 X15 160 (BAY 987516)Other: J & J baby shampoo, X46 046 (control)
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2018-12-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 83
- Registration Number
- NCT02802917
Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO
Phase 4
Completed
- Conditions
- Central Retinal Vein Occlusion
- Interventions
- First Posted Date
- 2016-06-15
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 162
- Registration Number
- NCT02800642
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
Phase 3
Completed
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer
- Interventions
- Drug: Standard ADT (androgen deprivation therapy)Drug: BAY1841788 / darolutamide (ODM-201)Drug: Placebo
- First Posted Date
- 2016-06-15
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1306
- Registration Number
- NCT02799602
Incidence of Second Primary Malignancies in Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the US
Completed
- Conditions
- Prostatic Neoplasms
- Interventions
- Other: Not applicable for study
- First Posted Date
- 2016-06-02
- Last Posted Date
- 2019-05-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2234
- Registration Number
- NCT02788409
18616 - Sun Protection Factor Assay
Not Applicable
Completed
- Conditions
- Sunscreening Agent
- Interventions
- Drug: Coppertone (BAY 987517)
- First Posted Date
- 2016-06-02
- Last Posted Date
- 2018-12-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 10
- Registration Number
- NCT02788162
© Copyright 2025. All Rights Reserved by MedPath